Rosadyn Study Results
Vascular Health Specialists (VHS), a firm dedicated to leveraging the latest dermatologic research to develop cutting-edge skin care products, is pleased to announce the pilot study results of their Rosadyn nutraceutical product, which targets flushing, redness and inflammation of facial skin.
Thirty-five (35) individuals who had been previously diagnosed with rosacea were selected and monitored through the first 4 weeks of an ongoing pilot study to evaluate the effect of Rosadyn on inflammatory skin symptoms. Participants took the daily-recommended dosage of Rosadyn and reported their progress via weekly online surveys conducted by the firm.
Findings
Participants reported improvement in a range of symptoms, most notably in the areas of flushing, redness and skin sensitivity. Highlights of the results by symptom are detailed below:
Flushing and Redness:
- 94% of participants reported a reduction in facial flushing with an average reduction level of 46.0%.
- 89% of participants reported a reduction in facial redness with an average reduction level of 44.5%.
- 66% of participants reported a reduction in broken blood vessels with an average reduction level of 39.5%.
- 60% of participants reported a reduction in facial swelling with an average reduction level of 38.0%.
Skin Sensitivity:
- 91% of participants reported a reduction in overall skin discomfort with an average reduction level of 51.3%.
- 89% of participants reported a reduction in hyper-sensitive skin with an average reduction level of 50.9%.
- 89% of participants reported a reduction in burning and stinging sensations with an average reduction level of 50.6%.
Papules and Pustules:
- 63% of participants reported a reduction in inflammatory papules (small red bumps) with an average reduction level of 38.6%.
- 31% of participants reported a reduction in inflammatory pustules (red bumps with pus) with an average reduction level of 29.5%.
Other Symptom Improvements:
- 91% of participants reported a reduction in anxiety during rosacea flares and triggers with an average reduction level of 48.0%.
- 51% of participants reported a reduction in global ocular rosacea symptoms with an average reduction level of 43.3%.
Side Effects
Participants were also asked to report any side effects associated with Rosadyn usage. The weekly survey included both a text box for participants to report any side effects in their own words, as well as a multiple choice question which asked testers to rate the level of any adverse reactions on a scale of 1-10, ranging from None, Mild, Moderate, to Severe.
In total, 89% of respondents reported no side effects at all. Of the remaining 11%, all reported effects were in the Mild range. There were no reports of any side effects at the Moderate or Severe level.
Overall Satisfaction
To gauge overall satisfaction with Rosadyn usage, participants were asked to rate the overall status of their rosacea symptoms after Rosadyn compared to pre-test levels. In total, 91% of testers reported an improvement in the overall status of their rosacea with an average improvement level of 49%. Moreover, in response to a question of whether participants would recommend the product to fellow rosacea sufferers, 75% indicated they would.
According to Dr. Geoffrey Nase, Ph.D, VHS’s founder and developer of Rosadyn, the results surpassed the expectations of the team, “While we certainly had faith that the pharmaceutical grade ingredients selected would target key symptoms, we were surprised at the speed and breadth of the reported improvements. We were particularly encouraged by the overall reduction in flushing, as this is an inherently unresponsive symptom. The pathophysiology behind such conditions involves months or years of chronic inflammation and cellular damage that usually takes time to reverse and normalize, so these findings exceeded our expectations. That said, the importance of continued supplementation must be emphasized as inflammatory skin symptoms often require several skin renewal cycles in order to maintain a healthy skin state.”
Dr. Bitter, Sr., a partner in VHS and collaborator on Rosadyn development, commented on the results, “It was particularly rewarding to see the heartfelt testimonials and gratitude from participants who have struggled with the condition for years with only negligible improvement at best.”
Deep Skin Inflammation and Skin Renewal
The Rosadyn Pilot study will continue to monitor the progress of testers at the two, three and six month periods. Early results indicate steady and continued improvement past the 4-week mark by most testers, highlighting the fact that the desired results may require at least 3 months (2 full skin-renewal cycles). More comprehensive testing of the affects on Rosadyn’s affect on rosacea symptoms are currently under development by Vascular Health Specialists. Additional Pilot Study details will be published shortly on the Rosadyn.com website.
About Vascular Health Specialists:
Vascular Health Specialists (VHS) is a firm dedicated to leveraging the latest dermatologic research to develop cutting edge products for rosacea and other skin conditions. Comprised of a team of professionals with backgrounds in medicine, research, business and skin care product development, VHS works closely with leading laboratories and nutraceutical manufacturers to remain at the forefront of novel skin treatments.
For more information, please visit the company website at: http://www.rosadyn.com.
See Also:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
We are pleased to announce that we are currently working on a Rosadyn Topical to reduce redness, flushing and skin inflammation. It will also include key ingredients to help gently clarify the skin.
Regards,
Geoffrey
Dr. Geoffrey Nase
Three of our top nutraceutical extracts in Rosadyn actually protect the skin from UV rays and damage when taken orally. In scientific and clinical studies the SPF is equivalent to an SPF of 25. We still recommend topical sun protection as an adjunctive protection.
I hope that helps.
Regards,
Dr. Geoffrey Nase
Oral Rosadyn Treatment for Rosacea [Update 02-03-10]:
We have invested in enteric coated, Pharmaceutical Grade, rapid-release capsules to ensure peak absorption and bioavailability.
Please visit our site to learn more about our latest advancements and vies new treatment photos:
Thank you.
Best Wishes,
Geoffrey
New enteric coated Rosadyn capsule to ensure all ingredients pass through acidic stomach environment in tact and bioavailable.
New Audio Testimonials at http://www.rosadyn.com
Kind regards,
Geoffrey
Please excuse the post above as that is from a disgruntled competitor. We just finished a six month clinical study on 55 moderate to severe rosacea sufferers. The results are excellent. Please visit our home page as we should have the entire clinical study online in Adobe PhotoShop Slide Show with photos, results and statistics.
Vascular Health Specialists is extremely pleased with our Rosadyn Study results. We have noted significant improvements beyond 4 weeks as it usually takes 3 to 4 skin renewal cycles to regain and maintain a healthy skin state.
http://www.pr.com/press-release/175341
We are finishing up a Rosacea Knowledge Forum that you can sign up for on our rosadyn page: http://rosadyn.com. This forum will be focused on continued treatment advancements and Vascular Health Specialists and I would like your feedback on what type of topical treatment or rosacea skin care product is needed the most.
Best wishes,
Geoffrey
Dr. Geoffrey Nase